Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that α-spinasterol treatment significantly reduced testosterone propionate-induced prostatic hyperplasia in rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.

This review discusses the advancements in understanding and treating androgenetic alopecia and alopecia areata but reports no clinical findings; the authors emphasize the need for further research on molecular control mechanisms.

This article reviews the causal mechanisms of hair follicle disorders, focusing on inflammation, genetics, environment, and hormones, but it reports no new clinical results.

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

This summary reviews the conflicting reports regarding 17β‐estradiol's effects on hair follicle growth, highlighting potential estrogen receptor-mediated impacts and calling for further research.

This article discusses various synthetic and herbal treatments for alopecia, noting limited effectiveness and associated side effects of synthetic options, and reports no new clinical results.

This review discusses the necessity for hair transplant surgeons to be well-versed in both surgical and medical treatments for various forms of alopecia, and it reports no new results.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

This review evaluates dihydrotestosterone's role in androgenic alopecia and proposes a model suggesting that chronic scalp tension and inflammation contribute to hair follicle miniaturization, identifying fibrosis, calcification, and tension as treatment targets.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This study found that coadministration of 5α-reductase inhibitors with oral testosterone in oil significantly increases serum testosterone levels in medically castrated men compared to testosterone alone, with food intake minimally affecting these levels.

Over 50% of women over 50 experience hair loss, with minoxidil being the only proven effective treatment.

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

This chapter reviews recent advances in 5α-reductase inhibitors for treating disorders mediated by dihydrotestosterone and reports no new clinical findings.

This review discusses the role of androgens in male sexual differentiation and characteristics and reports no new clinical results; it emphasizes the androgen dependence of male pattern scalp hair loss.

This review outlines that minoxidil (topical and oral) and 5α-reductase inhibitors are the most effective treatments for androgenetic alopecia, with additional therapies like platelet-rich plasma and hair transplantation enhancing results, emphasizing the need for individualized, combination approaches.

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This article discusses the hair follicle's regenerative cycles and the molecular mechanisms influencing them, emphasizing the need for therapeutic targeting of the "hair cycle clock" to manage hair growth disorders, without reporting new research findings.

This abstract discusses the unclear role of dihydrotestosterone (DHT) in postembryonic life in marsupials and possibly humans, reporting no new findings.

This review discusses the etio-pathogenetic factors in benign prostatic hyperplasia and their role in the development of lower urinary tract symptoms but reports no new research findings.

New treatments for male hypogonadism are effective and should be personalized.

This review discusses 46,XY disorders of sex development caused by defects in androgen production and highlights the need for long-term care from experienced multidisciplinary teams, but it reports no new clinical findings.

This review discusses the influence of androgens on hair and sebaceous growth, emphasizing that response may depend more on peripheral sensitivity than on hormone levels; it reports no new empirical results.

In this study, germacrone from Curcuma aeruginosa showed anti-androgenic effects by inhibiting 5α-reductase, suggesting its potential as a lead compound for treating androgen-dependent disorders.